Nevertheless, KIR blockade therapy also faces challenges, as evidenced by a phase II clinical trial evaluating KIR2D checkpoint inhibitors in multiple myeloma (MM) patients that failed to demonstrate clinical benefit as monotherapy. The gene discussed is KIR3DL1; the disease is Miyoshi myopathy.